1. Opening Hook

In a quarter where Trump reimposed tariffs like it’s 2018 again, Emcure casually announced its highest-ever quarterly profit. Revenue rose 15.7%, PAT jumped 41%, and management threw in a 5-year “next orbit” vision like a Marvel teaser. Bonus: retail investors literally reviewed Emcure’s moisturizing cream on the call — when your shareholders double up as dermatology influencers, you know the brand connect is deep.

2. At a Glance

• Revenue: ₹2,101 cr (↑15.7% YoY) – Balanced growth across India + exports.
• EBITDA: ₹404 cr (↑20% YoY) – Margins at 19.2%, climbing steadily.
• PAT: ₹215 cr (↑41% YoY) – Record profit, no doctor’s prescription needed.
• Domestic Biz: ₹995 cr (↑9.4% YoY) – Strong in Gynae, Cardiac, Vitamins.
• International Biz: ₹1,106 cr (↑22% YoY) – Canada, EU, EM all firing.
• Gross Debt: ₹700 cr – but CFO promises “almost zero soon”… barring more shopping sprees.

3. Management’s Key Commentary

“Revenue grew 15.7%, EBITDA 20%, PAT 41% — our best start ever.”
(Translation: Pharma’s monsoon quarter, but without the seasonal flu.)

“Sanofi diabetes brands Amaryl & Cetapin now in our fold.”
(Translation: We just hijacked diabetologists’ prescription pads.)

“Derma & Consumer Wellness are new growth drivers.”
(Translation: From cancer drugs to face cream — full spectrum hustle.)

“We are largely insulated from the US, exposure <3%.”
(Translation: Trump tariffs? Not our circus, not our monkeys.)

“5-year vision: invest in tech, people, processes, R&D.”
(Translation: Expect more buzzwords, but also more biosimilars.)

“Debt will be near zero… unless we buy something again.”
(Translation: CFO’s calculator is on a leash, but acquisitions bark louder.)

4. Numbers Decoded

5. Analyst Questions

• Domestic volume growth? Mgmt: 4% volume, 4% price, 1–2% new launches.
  (Translation: A perfect pharma thali — balanced serving sizes.)
• Sanofi diabetes portfolio scale? Mgmt: ~₹200 cr annualized, 8 months this year.
  (Translation: Sugar rush